2021 | 2022 | 2023 | 2024 | 2025 | |
---|---|---|---|---|---|
Revenue | $734M | $757M | $862M | $1B | $1.2B |
Cost of Revenue | $318M | $333M | $372M | $377M | $423M |
Gross Profit | $415M | $424M | $490M | $623M | $777M |
Gross Profit % | 57% | 56% | 57% | 62% | 65% |
R&D Expenses | $125M | $157M | $193M | $219M | $240M |
2021 | 2022 | 2023 | 2024 | 2025 | |
---|---|---|---|---|---|
Net Income | $8.8M | -$44M | -$26M | $56M | $97M |
Dep. & Amort. | $116M | $137M | $161M | $153M | $162M |
Def. Tax | -$5.1M | -$23M | -$17M | -$14M | -$13M |
Stock Comp. | $43M | $53M | $63M | $77M | $96M |
Chg. in WC | $12M | $1.6M | -$33M | -$33M | -$6.5M |
2021 | 2022 | 2023 | 2024 | 2025 | |
---|---|---|---|---|---|
Cash | $329M | $225M | $254M | $404M | $296M |
ST Investments | $0 | $0 | $0 | $0 | $0 |
Cash & ST Inv. | $329M | $225M | $254M | $404M | $296M |
Receivables | $73M | $87M | $97M | $105M | $118M |
Inventory | $0 | $0 | $1 | $0 | $0 |
HealthEquity reported strong Q4 FY2025 results with revenue up 19%, adjusted EBITDA up 9%, and HSA assets increasing 27% year-over-year to $32 billion.
The company achieved a milestone of 1 million new HSAs from sales in FY2025, ending the year with 17 million total accounts, including 9.9 million HSAs.
FY2026 guidance includes revenue between $1.28 billion and $1.305 billion, adjusted EBITDA between $525 million and $545 million, and non-GAAP net income between $318 million and $333 million.
Elevated service costs due to fraud prevention and cybersecurity measures are expected to normalize in the second half of FY2026, with continued investments in technology and security enhancements.
HealthEquity introduced its "Assist" portfolio, leveraging AI and data-driven tools to enhance member engagement, drive healthcare cost savings, and improve benefits plan ROI for employers.